Drug Profile
Research programme: immunology/inflammation antibody therapeutics - UCB
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator UCB
- Class Antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Immunological disorders; Inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Immunological-disorders in Belgium
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Belgium
- 09 Jan 2009 Preclinical trials in Immunological disorders in Belgium (unspecified route)